Evidence map›Paper›PMID 33236432›Full record

ArticlePediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology2020

One step closer to influenza vaccine inclusiveness.

Mayla Sgrulletti, Giorgio Ottaviano, Maria Sangerardi, Loredana Chini, Rosa Maria Dellepiane, Baldassarre Martire, Davide Montin, Caterina Rizzo, Viviana Moschese

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 79% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. One step closer to influenza vaccine inclusiveness.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Mayla SgrullettiPediatric Immunopathology and Allergology Unit, University of Rome Tor Vergata, Policlinico Tor Vergata, Rome, Italy.
Giorgio OttavianoMolecular and Cellular Immunology Unit, Great Ormond Street Institute of Child Health, University College of London, London, UK.
Maria SangerardiDepartment of Pediatrics and Emergency, Azienda Ospedaliero Universitaria Consorziale Policlinico, Ospedale Pediatrico "Giovanni XXIII", Bari, Italy.
Loredana ChiniPediatric Immunopathology and Allergology Unit, University of Rome Tor Vergata, Policlinico Tor Vergata, Rome, Italy.
Rosa Maria DellepianePediatric Intermediate Care Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Baldassarre MartirePediatrics and Neonatology Unit, Maternal-Infant Department, "Monsignor A.R. Dimiccoli" Hospital, Barletta, Italy.
Davide MontinDepartment of Public Health and Pediatrics, Regina Margherita Children Hospital, University of Turin, Turin, Italy.ORCID 0000-0001-8953-2182
Caterina RizzoInnovation and Clinical Pathways Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Viviana MoschesePediatric Immunopathology and Allergology Unit, University of Rome Tor Vergata, Policlinico Tor Vergata, Rome, Italy.ORCID 0000-0001-7650-0632
University of Rome Tor Vergata · ITBambino Gesù Children's Hospital · ITFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITGreat Ormond Street Hospital · GBOspedale Pediatrico Giovanni XXIII · ITOspedale Regina Margherita · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Flu virus infection is a common cause of acute respiratory illness, with the major incidence in pediatric age, high morbidity, and mortality. The flu vaccine is recommended for all people aged ≥6 months, unless specific contraindications are present. Younger and older age, pregnancy, chronic diseases like asthma, and immunodeficiency are risk factors for severe complications following flu infection. Thus, these categories represent the target for flu vaccine strategies in most countries. Inactivated influenza vaccine (IIV), recombinant influenza vaccine (RIV) or live-attenuated influenza virus (LAIV) are currently available, with specific precautions and contraindications. We aim to resume the current indications for vaccines in the vulnerable populations to support flu vaccination inclusiveness, in anticipation of a "universal vaccine" strategy.

Indexed as

AsthmaInfluenza, HumanInfluenza VaccinesAgedChildFemaleHumansPregnancyVaccinationVaccines, AttenuatedVaccines, InactivatedInfluenza VaccinesVaccines, AttenuatedVaccines, Inactivatedasthmachildrenimmunodeficiencyinfluenza vaccinepregnancyuniversal vaccine

Identifiers

PMID33236432
PMCPMC7753274
OpenAlexW3110430949

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.